Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma

BACKGROUND: The purpose of this study was to investigate the anti-tumor activities and the mechanisms of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib, combined with the anti-angiogenic target drug apatinib, in the treatment of lung adenocar...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Xiong, Zhi-Cheng, Sun, Xin, Sun, Li, Zhang, Shu-Ling, Ma, Jie-Tao, Han, Cheng-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798075/
https://www.ncbi.nlm.nih.gov/pubmed/35116965
http://dx.doi.org/10.21037/tcr.2019.09.35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798075/
https://www.ncbi.nlm.nih.gov/pubmed/35116965
http://dx.doi.org/10.21037/tcr.2019.09.35

Ejemplares similares